Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Psoriatic arthritis PsA is a chronic inflammatory condition affecting the joints and skin of people with psoriasis PsO. This research aims to evaluate how well the drug zasocitinib works in adults with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The study is a phase 3 trial comparing zasocitinib to an active comparator and placebo to assess treatment effects and safety. Participants are randomly assigned to one of four groups. One group receives zasocitinib Dose A orally once daily for up to 52 weeks, another group receives zasocitinib Dose B once daily for the same period, a third group receives the active comparator capsules twice daily for up to 52 weeks, and the fourth group receives placebo once daily for 16 weeks followed by zasocitinib Dose A or B from Week 16 to Week 52. This design allows comparison between different doses, placebo, and active treatments. During the study, participants will be monitored regularly with evaluations including joint assessments and skin lesion checks. Researchers will measure responses such as improvement in arthritis symptoms using the American College of Rheumatology 20 ACR20 response at Week 16 as the primary outcome. Secondary measures include skin improvement and various quality of life and disease activity scores. The study duration for participants is up to 60 weeks, including treatment and follow-up, to assess both efficacy and safety of the treatments.
Actively Recruiting
Healthy Volunteer
Researchers are conducting the ALL ALS Clinical Research Consortium study to collect a wide variety of samples, clinical data, and measurements from people with symptomatic Amyotrophic Lateral Sclerosis ALS, ALS gene carriers, and control participants without ALS. This study aims to create a harmonized data and sample repository to support future ALS and related neurological disease research. The study is funded by the NIHNINDS and coordinated across multiple clinical sites nationwide. Participants include symptomatic ALS patients and controls, with some ALS participants visiting clinics onsite and others participating remotely via video conferencing and home blood collection. The study follows participants for 24 months, during which medical history, clinical outcomes, and blood samples are collected every 4 months. Participants also complete monthly patient-reported outcomes and speech recordings. Optional cerebrospinal fluid samples may be collected at onsite visits. During the study, participants undergo assessments including the ALS Functional Rating Scale-Revised ALSFRS-R, cognitive testing, vital capacity measurements, hand muscle strength evaluations, and social and environmental history surveys. These are collected at scheduled intervals over two years. Data from these evaluations will help researchers understand ALS progression and characteristics. Participants involvement includes regular visits or remote sessions, with ongoing monitoring and data collection throughout the study period.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the feasibility and effectiveness of a breathwork and meditation program called Sudarshan Kriya Yoga SKY Breath for people with Parkinsons Disease iPD in stages 1, 2, and 3, who are under 75 years old, along with their care partners. The study aims to see if SKY Breath can reduce stress, improve mental and physical well-being, and relieve the emotional and physical burden on care partners. The research also explores how tailored the program can be to meet the unique needs of these individuals. The intervention consists of a 10-12 hour active learning phase over four mornings, where participants learn the SKY Breath and Meditation practice. Following this, participants practice daily at home for about 25 minutes, six days a week, supported by weekly instructor-led group sessionsone online and one in person. The program is adapted for each participants disability level, with parallel courses offered to care partners. The study timeline includes recruitment, baseline assessments, intervention phases, booster sessions, and follow-up evaluations up to eight weeks post-intervention. Participants will undergo evaluations before starting the program and at weeks 1, 4, and 8 after the intervention begins. These assessments include measures of stress, anxiety, depression, Parkinsons symptoms, and quality of life for both individuals with Parkinsons and their care partners. Participants will keep logs of their practice time and attend weekly sessions online and in person. The study involves repeated assessments to monitor changes in well-being and symptom management throughout the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of intranasal insulin combined with glutathione as an additional treatment for people with Parkinsons Disease. This phase II, randomized, double-blind, placebo-controlled study aims to compare these treatments against a placebo to better understand their impact on the condition. The study is sponsored by the Gateway Institute for Brain Research and seeks to explore new options for managing Parkinsons symptoms. Participants will be assigned to receive either the active drugsintranasal insulin Novolin R plus glutathioneor matching placebo treatments. These are administered twice daily as add-on therapies alongside participants usual medications. The study design includes a parallel group model where participants are monitored over a 24 to 28 week period to assess outcomes related to verbal fluency, motor function, cognitive function, non-motor symptoms, and patient-reported outcomes. During the study, participants will be closely monitored with evaluations of their verbal fluency at 24 weeks as the primary outcome measure. Secondary assessments include motor and cognitive function tests as well as reports on non-motor symptoms and overall patient well-being. Safety and tolerability of the treatments will also be carefully observed. Participants are expected to maintain consistent diets, exercise, and medication regimens throughout the trial. The total participation period extends up to approximately 28 weeks, with scheduled visits for assessments and monitoring.
Actively Recruiting
Researchers are studying the effects of non-invasive electrical stimulation on facial pain, jaw movement, chewing, and oral hygiene in people with Amyotrophic Lateral Sclerosis ALS and Primary Lateral Sclerosis PLS. The study aims to see if this treatment can reduce jaw pain and improve jaw mobility and chewing ability. It also looks at how the treatment might affect difficulty with oral hygiene tasks, based on patient reports. This is a prospective, cross-sectional study involving individuals diagnosed with ALS or PLS who experience jaw pain.
Actively Recruiting
This research aims to compare two pacing methods, His or Left bundle branch pacing HisLBBP and biventricular pacing BiVP, in patients with heart failure caused by left ventricular systolic dysfunction LVEF 50% who have either a wide QRS duration 130 ms or requireanticipate more than 40% pacing. The study focuses on patient-centered outcomes such as quality of life, physical activity, hospitalizations for heart failure, mortality, and device-related complications like lead dislodgement and infection, while participants continue standard heart failure medication. Participants are randomly assigned to receive either HisLBBP or BiVP devices. For patients with LVEF 35%, the HisLBBP group receives a defibrillator with three implanted leads, including a His-bundle or left bundle branch pacing lead, while those with LVEF 36-50% receive a pacemaker with two leads. The BiVP group receives a defibrillator with three leads for LVEF 35% and a pacemaker with three leads, including an epicardial left ventricular lead, for LVEF 36-50%. The pacing devices aim to synchronize heartbeats through different approaches to improve heart function. Throughout the study, participants are monitored for up to 5.5 years. Researchers will assess combined outcomes of all-cause death and heart failure hospitalizations as the primary measure. Secondary assessments include quality of life changes, psychological adjustment at one year, and heart function measured by left ventricular volume changes. Patient activity and heart failure symptoms will also be tracked using questionnaires, walk tests, and implanted device data. Safety and complications related to the devices will be closely followed during the study period.
Actively Recruiting
Healthy Volunteer
This research investigates how stress affects pregnant women, focusing on those experiencing repeated or chronic stress. The study aims to understand the journey pregnant women take to seek prenatal care and to develop models assessing the harmful health and biological impacts of social factors on stress during pregnancy. It also explores ways to reduce stress effects in pregnant women from diverse backgrounds who face high stress levels. Participants will be exposed to a mild 50-second stress stimulus followed by a 50-second relaxation period to record their physiological responses. After this initial assessment, they will independently practice simple stress management techniques at home, such as breathing exercises and listening to music, for one week. The study uses behavioral interventions to examine stress responses and management. During the study, researchers will monitor changes in stress levels over a 4 to 8 week period. Participants physiological responses to stress and relaxation will be recorded during the sessions. The study includes follow-up assessments to evaluate how stress management impacts these measures. Overall participation will span several weeks to capture changes and effects of the interventions on stress.
Actively Recruiting
This observational registry study is designed to continuously evaluate and periodically report on the safety and effectiveness of Medtronic market-released medical products. It aims to support patients, hospitals, clinicians, regulatory bodies, payers, and the medical industry by streamlining clinical surveillance and enhancing performance assessment with minimal burden. Participants include patients who have received or are intended to receive an eligible Medtronic product. The registry collects data related to various conditions such as cardiac rhythm disorders, neurological disorders, cardiovascular disorders, and several others, with ongoing monitoring every 6 to 12 months depending on the therapy. During the study, participants provide consent and data is collected during routine care and follow-up visits. The research team reviews safety and effectiveness outcomes regularly to understand product performance over time. The study is planned to continue until January 2040, allowing for long-term monitoring and reporting.
Actively Recruiting
Healthy Volunteer
This research focuses on treating intra-bony defects caused by periodontal disease, which can lead to changes in bone structure around teeth. The study evaluates and compares two treatments to improve bone regeneration and periodontal health recombinant human platelet derived growth factor rh-PDGF combined with bone allograft versus enamel matrix derivatives EMD combined with bone allograft. The goal is to assess the effectiveness of these therapies in patients with persistent deep probing depths and intra-bony defects. Participants will be randomly assigned to one of two groups. One group will receive rh-PDGF GEM-21 with allogenic bone graft, and the other group will receive EMD with allograft. Both groups will undergo the same surgical procedure. The study includes follow-up visits at 6 and 12 months after treatment to monitor progress and re-evaluate the results. During the study, patients will be assessed for clinical attachment changes and other periodontal health measures. Researchers will perform evaluations including probing depth measurements and radiographic imaging to observe bone gain and attachment improvements. The study aims to monitor treatment outcomes over a 12-month period, with safety and effectiveness assessments at specified intervals.
Actively Recruiting
Gulf War Illness affects multiple major organ systems and causes symptoms such as severe fatigue, memory and thinking difficulties, headaches, sleep problems, digestive issues, skin rashes, and joint pain. This phase II, double-masked, randomized, placebo-controlled study investigates whether the dietary supplement Bacopa can help manage central nervous system symptoms of Gulf War Illness. The study focuses on evaluating cognitive function and safety of Bacopa in affected Gulf War Veterans born between 1942 and 1978 who meet specific case definitions for the illness. Participants will be randomly assigned to one of two groups one receives 300 mg daily of BacoMind4 Bacopa monnieri standardized extract for 12 weeks, and the other receives a placebo that looks identical. The treatment period lasts 12 weeks, with follow-up assessments continuing for an additional 4 weeks after treatment ends. The study is conducted remotely using online tools and telephone interviews, and laboratory tests are done locally for a subgroup of participants to measure biomarkers related to brain health and inflammation. During the study, participants will be assessed at baseline, 6, 12, and 16 weeks for cognitive performance using the California Verbal Learning Test CVLT-II, physical health, vitality, sleep, pain, and symptom severity. Blood samples will be collected at baseline and at 12 weeks for some participants. Safety will be monitored through biweekly phone calls. The total observation period covers 16 weeks to evaluate both immediate and lasting effects of the treatment.
1-10 of 11
1